The plasminogen activation system: New targets in lung inflammation and remodeling

Michael Schuliga, Glen Westall, Yuxiu Xia, Alastair G. Stewart

Research output: Contribution to journalReview ArticleResearchpeer-review

31 Citations (Scopus)


The plasminogen activation system (PAS) and the plasmin it forms have dual roles in chronic respiratory diseases including asthma, chronic obstructive pulmonary disease and interstitial lung disease. Whilst plasmin-mediated airspace fibrinolysis is beneficial, interstitial plasmin contributes to lung dysfunction because of its pro-inflammatory and tissue remodeling activities. Recent studies highlight the potential of fibrinolytic agents, including small molecule inhibitors of plasminogen activator inhibitor-1 (PAI-1), as treatments for chronic respiratory disease. Current data also suggest that interstitial urokinase plasminogen activator is an important mediator of lung inflammation and remodeling. However, further preclinical characterization of uPA as a drug target for lung disease is required. Here we review the concept of selectively targeting the contributions of PAS to treat chronic respiratory disease.

Original languageEnglish
Pages (from-to)386-393
Number of pages8
JournalCurrent Opinion in Pharmacology
Issue number3
Publication statusPublished - Jun 2013
Externally publishedYes

Cite this